Loading clinical trials...
Loading clinical trials...
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Conditions
Interventions
Pegozafermin
Placebo
Locations
331
United States
89bio Clinical Study Site
Birmingham, Alabama, United States
89bio Clinical Study Site
Chandler, Arizona, United States
89bio Clinical Study Site
Flagstaff, Arizona, United States
89bio Clinical Study Site
Glendale, Arizona, United States
89bio Clinical Study Site
Tucson, Arizona, United States
89bio Clinical Study Site
Conway, Arkansas, United States
Start Date
March 13, 2024
Primary Completion Date
February 1, 2029
Completion Date
February 1, 2029
Last Updated
February 11, 2026
Lead Sponsor
89bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions